A Houston space medicine research organization has partnered with a video game maker that has created surgery simulation technology. Photo via levelex.com

A Houston-based organization affiliated with NASA has teamed up with a video game company to advance virtual simulation in space medicine.

The Translational Research Institute for Space Health, known as TRISH, in partnership with NASA in a consortium led by Baylor College of Medicine, California Institute of Technology in Pasadena, and Massachusetts Institute of Technology in Cambridge has advanced a new approach for space medicine using video game technology by collaborating with video game company, Level Ex.

"We discovered Level Ex through a process of landscaping the many virtual simulation companies that were out there," says Andrew Peterman Director of Information System at TRISH. "We especially noted those that were on the cutting edge of the technology."

Based in Houston, TRISH aims to collaborate with the best and the brightest to revolutionize space health, providing grants to companies with innovative concepts. With Level Ex, they found a new approach to decode earthly medical technologies in space.

Level Ex, a Chicago-based company created in 2015 was founded to provide training games for doctors to use to practice surgeries and procedures. The games are interactive, with the virtual patient reacting to the actions of the player. The training simulations consist of in-depth and physics-driven medical simulations that are verified by doctors in their advisory board.

"We're hoping to completely change the ways that doctors stay up to speed," says Level Ex founder-and-CEO Sam Glassnberg.

With their ongoing collaboration with TRISH, they have a challenge that's out of this world. In space, astronauts have limited space for medical tools and run on a limited crew. This makes providing basic medical training to all astronauts especially important.

Especially since the body begins to react to the new environmental conditions of space missions. The effects can be small or lead to new changes or challenges for astronauts who take on long-range missions. Astronauts may see their bodies slowly start to lose bone and muscle mass. Their fluid begins to shift toward their head, leading to increased risks of hypertension and thrombosis.

All of these are challenges NASA is working to address with the help of gaming technology from Level Ex that innovates the technology with higher-level capability and training. Combining video game technology and medical simulation applications to incorporate and explore the interplay of environmental conditions found in space.

"What we really liked about Level Ex is that they have an amazing team both on the clinical and technical side, says Peterman. "They are a group of former big-name game developers who along with clinical experts have married technology and medicine with their platform producing full in engine physics-driven real simulations rather than video playback."

The astronauts will train using simulations that allow them to practice a procedure in zero gravity conditions and even simulate the gravity conditions of Mars. The game will also allow astronauts to get their own on-screen avatar with their medical information thus allowing fellow astronauts to gain more practice and experience with fewer variables in space.

The advanced medical simulation platform has potential for commercial uses on earth, improving the range of the technology to simulate new, rare, and complex scenarios across a range of medical specialties, allowing doctors to practice a range of difficult scenarios without putting patient lives at risk.

Peterman says that the partnership is expected to continue into the future for immediate applications along with other innovations in astronaut healthcare, including autonomous frameworks to provide medical knowledge in outer space.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.